#6814 A NEW SORBENT DEVICE FOR MULTIPLE CLINICAL PURPOSES: CURRENT EVIDENCE AT A PRIVATE HOSPITAL IN MEXICO

Abstract Background and Aims Adsorption is an extracorporeal technique utilized for blood purification, it also complements convection diffusion solute removal. Since 1991 we had used purification techniques, over the years, new adsorption cartridges been developed, ones involving treatment inflammatory conditions, chronic uremic symptoms autoimmune diseases. HA130, HA230, HA330 (Jafron, Zhuhai City, China) are among widely in China. We report highlights of use hemoperfusion using HA130 Mexican population cohorts context multiple conditions order to support evidence effectiveness safety. Method retrospectively analyzed medical records 14 critically ill patients such as acute kidney injury disease, lung due SARS-COV-2 infection sepsis. Hemoperfusion addition standard therapy (fluid resuscitation, vasopressors, antimicrobial ventilatory support) resulted improvement substances levels when compared alone. Out patients, 7 with Results There were no significant side effects associated cartridge use. HA 130 found be effective reducing hemodialysis pruritus score decreased parathyroid hormone phosphate product (p<0.5) HD alone, creatinine (MARS: −24 μmol/L, −19.5 −10.46, p < 0.001; SPAD: −2 −9.0 +7.0/L, = 0.314) urea −0.9 mmol/L, −318 −0.189, 0.024; −0.1 −1.0 +0.68, 0.523). 66.6% cost-effectiveness therapy. Conclusion In group that statistically (p <0.05) reduction score, PTH, product, creatine The development technology allows more wide applications renal patients. As expand involve other indications this there patients.More studies different clinical settings needed achieve national recommendations. microinflammatory status disease elimination middle small molecule toxins mediators endotoxins. This may translate quality life survive rates hemodialysis, even though prove assumption.